An important update regarding registration and supply of Prochlorperazine. Prochlorperazine 3mg buccal tablets are now registered and listed on the Schedule*

FREE READ

+Undoctored

An important update regarding registration and supply of Prochlorperazine. Prochlorperazine 3mg buccal tablets are now registered and listed on the Schedule*

Media release from Max Health

Friday 28 March 2025, 04:42 PM

Max Health is pleased to announce a resolution to the recent issues with Prochlorperazine 3mg buccal tablets.

Max Health Director David Pascoe, said, “in order to address the needs of the New Zealand market, we have partnered with UK company Brown and Burk to achieve Medsafe registration of Prochlorperazine 3mg buccal tablets and ongoing supply for our local market.”

Prochlorperazine is indicated for a variety of conditions including:

the symptomatic treatment of vertigo due to Meniere's Disease, Labyrinthitis and other causes
nausea and vomiting from whatever cause and
in the treatment of migraine¹.

Max Health's prochlorperazine 3mg buccal tablets are now:

Medsafe registered and
listed on the Pharmaceutical Schedule*.

*A part-charge will apply

References

1. Prochlorperazine data sheet, December 2024, www.medsafe.govt.nz

Indications: Prochlorperazine maleate is indicated in adults & children >12 yrs: Symptomatic treatment of vertigo due to Meniere's Disease, Labyrinthitis and other causes; For nausea and vomiting from whatever cause; In the treatment of migraine. 

Warnings & Precautions: Use with caution in patients with stroke risk factors; myasthenia gravis; AIDS; hypotension; dementia; neuroleptic malignant syndrome; venous thromboembolism; QT prolongation & carbohydrate malabsorption disorders.

Interactions: Alcohol, CNS depressants; antihypertensives; neuroleptics; anticoagulants; Anticonvulsants; lithium; desferrioxamine; levodopa; anti-arrhythmics, antidepressants, macrolide-antibiotics & other antipsychotics. 

Prochlorperazine maleate is a partially funded prescription only medicine. Please review the full Data Sheet before prescribing. Data sheets are available at www.medsafe.govt.nz .

Distributed by Max Health Ltd, Auckland. Date of Preparation March 2025. MXH/NZ/PROCHLORPERAZINE/002.

Undoctored archive

How to Treat

+How to treat

Polypharmacy

For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews

Wednesday 28 May 2025, 12:50 AM